Prelude therapeutics announces first quarter 2021 financial results and operations update

- enrollment now underway in multiple solid tumor and hematologic malignancy expansion cohorts in phase 1 trial of oral prmt5 inhibitor prt543 -

PRLD Ratings Summary

PRLD Quant Ranking